MELAFLASH SET’s clinical results that change the landscape
Published a few months ago, this article presented the MELAFLASH SET protocol as a promising approach in the management of hyperpigmentation, based on solid pathophysiological foundations and an ongoing clinical study. New clinical data is now available, making it possible to validate both the tolerability and efficacy of this innovative protocol.
Moving Beyond the Anti Tyrosinase Approach
The management of pigmentary disorders remains one of the greatest challenges in aesthetic dermatology. While tyrosinase inhibition has long been considered the standard of care, it is often insufficient to address the inflammatory and vascular components of hyperpigmentation. This is precisely where DermEden’s expertise comes into play, with a protocol whose efficacy is now validated by a dermatologist supervised clinical study.
Tranexamic Acid: A Unique Depigmenting ACTION
At the core of this advancement lies Tranexamic Acid (TXA). Historically used for its coagulation properties, this active ingredient is now widely recognised for its unique ability to inhibit the plasminogen pathway. By reducing inflammatory and vascular mediators and limiting melanosome transfer, TXA—here combined with Niacinamide—provides a targeted response to inflammatory mediators responsible for pigment rebound.
This makes it particularly effective in the management of melasma, POH, PIH, and post acne hyperpigmentation, conditions for which tyrosinase inhibition alone is insufficient.
“TXA is not only perfectly well tolerated, but it also proves to be as effective as hydroquinone—the reference treatment—without its classic limitations.”
For more information: www.DERMEDEN.com
